Destiny Pharma Announces Qualified Infectious Disease Product Designation Granted by US FDAfor XF-73 Dermal Gel for Treatment of Burn Wound Infections

Destiny Pharma initiates research to explore XF drug potential for CF

Director/PDMR Shareholding

XF-73 prevents bacterial invasion of bloodstream

Result of GM and Cancellation of Trading on AIM
